Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to ...

Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to assess the levels of 5,400 different ...

The wheels of the antibody-drug conjugate (ADC) juggernaut keep on turning, with Araris Biotech AG announcing a deal with a ...

New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and ...

In the Jan. 1, 2025, issue of Nature, researchers from the Allen Institute presented a map of areas and cell types where ...

Immune checkpoint blockade is one of the major advances in cancer treatment in recent years. However, the majority of immune ...

BioWorld biopharma clinical, regulatory and conference charts include worldwide news of phase I, phase II and phase III clinical development by biopharmaceutical companies developing therapeutics, as ...

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 ...

South Korea’s government continued to ramp up investment in its pharmaceutical and med-tech sector in 2025, including a 7.2% ...

Data from two out of three positive studies faced the U.S. FDA’s Anesthetic and Analgesic Drug Products Advisory Committee as members examined the package submitted by Seikagaku Corp., of Tokyo, for ...

Climb Bio Inc. has entered into an exclusive license agreement with Beijing Mabworks Biotech Co. Ltd. for rights to develop and commercialize MIL-116 (now CLYM-116), an anti-APRIL monoclonal antibody ...

Researchers from Vera Salus Ricerca Srl and affiliated organizations have reported the discovery and preclinical characterization of novel sigma-1 receptor (S1R) antagonists as potential new analgesic ...